GSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from Brokerages

GSK plc (LON:GSK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is GBX 1,805.83 ($21.97).

Several research analysts recently issued reports on GSK shares. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank cut their price objective on GSK from GBX 1,820 ($22.14) to GBX 1,600 ($19.47) and set a "buy" rating for the company in a report on Friday, November 29th.

GSK Price Performance

GSK traded up GBX 14.76 ($0.18) on Tuesday, reaching GBX 1,363.26 ($16.59). The company had a trading volume of 9,797,177 shares, compared to its average volume of 55,508,164. GSK has a 52-week low of GBX 1,282.50 ($15.60) and a 52-week high of GBX 1,823.50 ($22.19). The company has a market cap of £55.62 billion, a price-to-earnings ratio of 1,206.42, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The business has a 50 day simple moving average of GBX 1,344.09 and a 200 day simple moving average of GBX 1,470.63.

GSK Announces Dividend

The business also recently declared a dividend, which was paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th were given a GBX 15 ($0.18) dividend. The ex-dividend date of this dividend was Thursday, November 14th. This represents a dividend yield of 1.03%. GSK's dividend payout ratio is currently 5,309.73%.

Insiders Place Their Bets

In other news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The stock was acquired at an average cost of GBX 1,315 ($16.00) per share, for a total transaction of £19,725 ($23,999.27). Over the last three months, insiders have purchased 8,658 shares of company stock valued at $11,950,792. 1.61% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.